# What the 2026 FDA Appraisal Found About Semax and Stroke

- Article ID: research-333
- Product: Semax (semax-704)
- Canonical page: https://heritagebiolabs.com/research-library/articles/333-what-the-2026-fda-appraisal-found-about-semax-and-stroke
- Product collection: https://heritagebiolabs.com/research-library/products/semax
- Product page: https://heritagebiolabs.com/product/semax-704
- Reading focus: Study findings (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2018, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short chains of amino acids linked by peptide bonds. Scientists can study them to learn how nerve cells respond to a loss of blood flow or to signals involved in recovery. Semax is a synthetic seven-amino-acid peptide derived in part from a region of adrenocorticotropic hormone. It has been studied in relation to cerebral ischemia, a loss of adequate blood flow to brain tissue. A 2026 FDA briefing evaluated the evidence for certain proposed compounding uses and identified important limits. [1]

One older human report by Gusev and colleagues examined 110 people after ischemic stroke. The researchers compared subgroups in earlier and later rehabilitation and reported observations for blood levels of brain-derived neurotrophic factor, motor measures and the Barthel Index, a measure of daily function. The abstract describes favorable associations in some comparisons. It does not supply all the details needed to assess assignment, masking and other aspects of the clinical design. The timing of rehabilitation also differed among groups. [2]

In the 2026 briefing, FDA explained that several reports were not available in a form it could evaluate under its translation requirements. It found the assessable clinical information insufficient to establish effectiveness for cerebral ischemia. That assessment is not a claim that nobody has studied Semax in people. It describes what the available evidence could establish for the proposed use. [1]

A marker in blood, an observation during rehabilitation and an outcome in a randomized acute stroke trial are different kinds of evidence. To evaluate a treatment claim, the key questions are which people were studied, when they received the intervention and whether it changed function against a sound comparison. The present evidence does not settle those questions for the proposed use. [1, 2]

## Sources

1. US Food and Drug Administration. FDA Briefing Document for Semax-Related Bulk Drug Substances. Pharmacy Compounding Advisory Committee (2026-07-23). <https://www.fda.gov/media/193348/download>
2. Gusev EI et al. The efficacy of semax in the tretament of patients at different stages of ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova (2018). <https://pubmed.ncbi.nlm.nih.gov/29798983/>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 067 - SEMA IGF-1 LR3 and Semax.docx; article 333; content SHA-256 b5fe671f478a1544770ff9e7a3902c4ae7f69f51302bf1ddb1efbf8473eb46e7.
